KalVista Pharmaceuticals announced the appointment of Nicole Sweeny as Chief Commercial Officer. Sweeny has more than 20 years of commercial strategy and leadership experience and has launched several approved products for rare diseases, including HAE. Sweeny previously was US Franchise Head of the Hereditary Angioedema team at Takeda Pharmaceuticals where she was responsible for the US launch of the market-leading HAE prophylaxis
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KALV:
